EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis

Ping Li, Yu An, Hongguang Zheng, Weiping Lu, Zhaohui Mo, Xudong Xu, Yibing Lu, Chaoqing Wu, Jingyuan Xie, Nanwei Tong, Fang Liu, Qinkai Chen, Jingjing Tang, Meike Brinker, Luke Roberts, Dalong Zhu, Zhihong Liu

Kidney Diseases · 2026-02-03 · 12 (1) · 318-329

DOI: 10.1159/000550850 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduced the risk of heart and kidney outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD trials. This subanalysis explored the efficacy and safety of finerenone vs. placebo in Chinese patients. Methods: Patients with CKD (urine albumin-to-creatinine ratio 30–5,000 mg/g, estimated glomerular filtration rate [eGFR] ≥25 mL/min/1.73 m2) and T2D, on optimized renin-angiotensin system inhibitors, were randomized 1:1 to finerenone or placebo. Key outcomes included a kidney composite (kidney failure, sustained ≥57% eGFR decrease from baseline over ≥4 weeks, or kidney-related death) and a cardiovascular (CV) composite (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure). An additional kidney composite outcome was kidney failure, sustained ≥40% eGFR decrease from baseline over ≥4 weeks, or kidney-related death. Treatment-emergent adverse events were also assessed. Results: In this Chinese patient subanalysis (n = 697), finerenone reduced the risk of the ≥57% and ≥40% kidney composite outcomes (hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.38–0.86; p = 0.0066 and HR: 0.54; 95% CI: 0.40−0.74; p < 0.0001, respectively) and CV composite outcome risk vs. placebo (HR: 0.82; 95% CI: 0.52–1.29; p = 0.3866). Safety outcomes were similar between treatment arms. Hyperkalemia leading to treatment discontinuation was low for finerenone (2.6%) and placebo (0.9%). Conclusion: Finerenone demonstrated kidney benefits, favorable trends on CV outcome, and a manageable safety profile in the FIDELITY Chinese subpopulation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →